DexCom Debt/Equity Ratio 2010-2024 | DXCM

DexCom debt/equity ratio for the quarter ending September 30, 2024 was 1.23.

  • DexCom average debt/equity ratio for 2023 was 0.99, a 16.47% increase from 2022.
  • DexCom average debt/equity ratio for 2022 was 0.85, a 3.41% increase from 2021.
  • DexCom average debt/equity ratio for 2021 was 0.88, a 20% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

DexCom Debt/Equity Ratio 2010-2024 | DXCM

  • DexCom average debt/equity ratio for 2023 was 0.99, a 16.47% increase from 2022.
  • DexCom average debt/equity ratio for 2022 was 0.85, a 3.41% increase from 2021.
  • DexCom average debt/equity ratio for 2021 was 0.88, a 20% decline from 2020.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$214.1B
Intuitive Surgical (ISRG)$183.6B
Alcon (ALC)$45.1B
IQVIA Holdings (IQV)$40.2B
Edwards Lifesciences (EW)$39.6B
IDEXX Laboratories (IDXX)$34.7B
Waters (WAT)$23B
STERIS (STE)$22.4B
SONOVA HOLDING (SONVY)$21.9B
Hologic (HOLX)$18.7B
Fresenius Medical Care AG KGaA (FMS)$12.4B
Sysmex ADR (SSMXY)$11.9B
Globus Medical (GMED)$11.2B
Teleflex (TFX)$9.4B
Penumbra (PEN)$9B
Masimo (MASI)$8.9B
Glaukos (GKOS)$7.8B
PROCEPT BioRobotics (PRCT)$5.1B
Integer Holdings (ITGR)$4.5B
Inari Medical (NARI)$3.1B
TransMedics (TMDX)$2.9B
LivaNova (LIVN)$2.8B
Veracyte (VCYT)$2.8B
Nihon Kohden (NHNKY)$2.5B
Tandem Diabetes Care (TNDM)$2.2B
Elekta AB (EKTAY)$2.2B
Integra LifeSciences Holdings (IART)$2.1B
RxSight (RXST)$2B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B